Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Verapamil
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Verapamil
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable